{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-080622","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2026-07-23T11:30:22+00:00","discovered_at":"2026-07-23T11:35:00.282977+00:00","generated_at":"2026-07-23T11:35:16.116366+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Incannex commences participant screening in Phase 2 DReAMzz study of IHL-42X for obstructive sleep apnea","bullets":["First clinical sites approved and actively screening participants for DReAMzz Phase 2 dose confirmation study of IHL-42X.","IHL-42X has FDA Fast Track designation, supporting potentially expedited regulatory pathway.","Prior Phase 2 data showed up to 83% reduction in AHI and significant improvements in patient-reported outcomes.","No FDA-approved oral pharmaceutical therapies currently available for OSA, affecting ~1 billion people globally.","Study designed to optimize dosing profile and strengthen regulatory package ahead of planned Phase III development."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-080622","json":"https://secwatch.observer/filing/0001213900-26-080622.json","markdown":"https://secwatch.observer/filing/0001213900-26-080622.md","text":"https://secwatch.observer/filing/0001213900-26-080622.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026080622/0001213900-26-080622-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026080622/ea0298674-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-23T11:35:16.116366+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}